Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2011 Financial Results on August 3, 2011
Date:7/27/2011

SAN DIEGO, July 27, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its second quarter ended June 30, 2011 financial results on Wednesday, August 3, 2011.

Cadence management will host a conference call and live webcast to discuss the financial results on Wednesday, August 3, 2011 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing (877) 303-9145 (domestic) or (760) 536-5203 (international).  To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investor Relations page.  A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. In January 2011, Cadence commercially launched OFIRMEV™ (acetaminophen) injection, an intravenous formulation of acetaminophen, in the U.S.  For more information about Cadence, please visit www.cadencepharm.com.Contacts:

William R. LaRueSVP & Chief Financial OfficerCadence Pharmaceuticals, Inc.858-436-1400
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
2. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
3. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
5. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
6. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
7. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
9. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Md. , March 24, 2017  Infectex Ltd., ... (MBVF), today announced positive results of a Phase 2b-3 ... therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). ... scientists at Sequella, Inc. ( USA ) ... A total of 140 patients were enrolled in ...
(Date:3/24/2017)... Mass. , March 24, 2017 Agenus ... of immune checkpoint antibodies and cancer vaccines, today announced ... The 7 th  Annual William Blair and Maidstone Life ... Space Alexandria Center in New York, NY ... March 29 at 9:40 am: Robert ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... ... causes of death, putting significant strain on health care systems, ... of cancer diagnoses rises, so too does the development of ... with minimum side effects. Among the many types of cancer ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Summary ... better understand Merck KGaA and its partnering interests and ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
Breaking Biology News(10 mins):